Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer

BJU International

Volumn 101, Issue 8, 2008, Pages 959-963

  Ramsey, Sara ^a   Lamb, Gavin W A ^a   Aitchison, Michael ^a   McMillan, Donald C ^b  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Albumin; C reactive protein; Cancer specific survival; Lymphocytes; Neutrophils; Performance status; Platelets; Renal cancer; White cells

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; INFLAMMATION; KATTAN SCORE; KIDNEY CANCER; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; NEUTROPHIL COUNT; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SCORING SYSTEM; STAGE SIZE GRADE NECROSIS; THROMBOCYTE COUNT; UNIVERSITY OF CALIFORNIA LOS ANGELES INTEGRATED STAGING SYSTEM;

ADULT; AGED; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; NEPHRITIS; PROGNOSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 41049098453     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07363.x     Document Type: Article

References (35)

1. Cancer Research UK. Kidney cancer survival statistics. Available at: http://info.cancerresearchuk.org/cancerstats/types/kidney/survival/. Accessed November 2007
2. Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002 20 : 4559 66
3. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis the SSIGN score. J Urol 2002 168 : 2395 400
4. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001 166 : 63 7
5. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 2001 41 : 64 9
6. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003 89 : 1028 30
7. Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 2006 6 : 450 3
8. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer 2006 94 : 637 41
9. Bromwich E, McMillan DC, Lamb GW, Vasey PA, Aitchison M. The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer 2004 91 : 1236 8
10. Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 2007 109 : 205 12
11. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003 90 : 215 9
12. Jamieson NB, Glen P, McMillan DC et al. Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 2005 92 : 21 3
13. Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 2006 94 : 1568 71
14. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 2007 22 : 881 6
15. Lamb GW, McMillan DC, Ramsey S, Aitchison M. The relationship between the pre-operative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer 2006 94 : 781 4
16. Royston P, Sauerbrei W, Ritchie A. Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions. Br J Cancer 2004 90 : 794 9
17. Atzpodien J, Royston P, Wandert T, Reitz M. DGCIN - German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003 88 : 348 53
18. Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F, Nespoli A. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 2003 26 : 394 402
19. Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res 2003 9 : 3562 70
20. Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000 86 : 203 7
21. Bensalah K, Leray E, Fergelot P et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 2006 175 : 859 63
22. Suppiah R, Shaheen PE, Elson P et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 2006 107 : 1793 800
23. Sobin L, Wittekind C, International Union Against Cancer. UICC. TNM Classification of Malignant Tumors, 5th edn. New York : Wiley-Liss, 1997 : 180 2
24. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982 6 : 655 63
25. O'Gorman P, McMillan DC, McArdle CS. Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer. Nutr Cancer 1999 35 : 127 9
26. Karakiewicz PI, Hutterer GC, Trinh QD et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 2007 110 : 1241 7
27. O'Keefe SC, Marshall FF, Issa MM, Harmon MP, Petros JA. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol 2002 168 : 1378 80
28. Gogus C, Baltaci S, Filiz E, Elhan A, Beduk Y. Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 2004 63 : 447 50
29. Inoue K, Kohashikawa K, Suzuki S, Shimada M, Yoshida H. Prognostic significance of thrombocytosis in renal cell carcinoma patients. Int J Urol 2004 11 : 364 7
30. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 2006 13 : 1365 70
31. Ramsey S, Lamb GW, Aitchison M, McMillan DC. The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer. Br J Cancer 2006 95 : 1076 80
32. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996 9 : 532 62
33. Bromwich EJ, McArdle PA, Canna K et al. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 2003 89 : 1906 8
34. Thompson RH, Gillett MD, Cheville JC et al. Costimulatory B7-H1 in renal cell carcinoma patients. Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004 101 : 17174 9
35. Salgado R, Vermeulen PB, Benoy I et al. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999 80 : 892 7